QPQuoc Thang Pham

Quoc Thang Pham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Quoc Thang Pham has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Wataru Yasui

    Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

    9 shared publications
  • Daiki Taniyama

    Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan

    7 shared publications
  • Kazuhiro Sentani

    Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan

    7 shared publications
  • Yohei Sekino

    Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

    6 shared publications
  • Dat Quoc Ngo

    Department of Histology, Embryology and Pathology, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam

    5 shared publications
  • Naohide Oue

    Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

    5 shared publications

Latest Publications

  • Open Access

    Pan-TRK expression in mismatch repair-deficient colorectal adenocarcinoma: prevalence and clinicopathological correlates in a Vietnamese cohort

    by Thu Anh Duong, Quoc Thang Pham, Thanh Toan Nguyen, Quang Vu Tran, Thanh Thien Ly, Minh Huy Le, Anh Tu Thai, Quoc Dat Ngo

    Deficient mismatch repair/high microsatellite instability (dMMR/MSI-H) colorectal cancer (CRC) represents a distinct molecular subgroup with therapeutic implications, particularly in the context of immunotherapy and emerging targeted treatments. NTRK rearrangements are enriched in dMMR colorectal adenocarcinoma compared to pMMR tumors, creating a critical opportunity for targeted therapy with TRK-inhibitors. Our study aimed to evaluate the frequency of pan-TRK expression in dMMR colorectal adenocarcinoma. We conducted a retrospective cross-sectional study of 211 patients with histologically confirmed dMMR CRC who underwent surgical resection at two tertiary centers in Ho Chi Minh City between 2020 and 2024. Mismatch repair status was determined by immunohistochemistry (IHC) using MLH1, PMS2, MSH2, and MSH6 antibodies. Tissue microarrays were constructed, and pan-TRK expression was assessed using IHC (clone EPR17341). Among the 211 analyzed cases, we identified 15 tumors (7.1%) with positive pan-TRK expression, including 12 cases that exhibited membranous staining, whereas 3 cases demonstrated cytoplasmic pattern. We did not observe nuclear staining in any tumor. Most of positive tumors (93%) exhibited a diffuse staining pattern. We observed a higher frequency of pan-TRK expression in tumors exhibiting specific clinicopathological features, including proximal colon location, mucinous histology, high-grade morphology, and lymphovascular invasion. Additionally, most positive cases exhibited concurrent MLH1/PMS2 loss. However, these associations did not reach statistical significance. To our knowledge, this study represents the first comprehensive analysis of pan-TRK expression in Vietnamese patients with dMMR CRC. Our findings highlight its potential clinical relevance and provide a basis for future molecular studies, with possible implications for targeted therapeutic strategies.

  • Open Access

    Deficient Mismatch Repair Subtypes in Vietnamese Colorectal Cancer: Clinicopathologic Associations, Predictive Modeling, and IHC-PCR Concordance

    by Hoang Duc Trinh, Quoc Thang Pham, Nguyen Hong Phong, Tran Thi Huong Ly, Quoc Chuong Ho, Hoang Anh Vu, Vo Kha, Quoc Dat Ngo

    Background: Microsatellite instability (MSI) caused by deficient mismatch repair (dMMR) influences prognosis and immunotherapy response in colorectal cancer. The dMMR phenotype includes MutL-deficient (dMutL) and MutS-deficient (dMutS) subtypes, which may differ in their clinicopathologic profiles, yet data from Southeast Asian populations remain limited. Our study aimed to investigate the associations between clinicopathological features with MSI/dMMR status and concordance in dMMR identification between immunohistochemistry (IHC) and polymerase-chain reaction (PCR) in Vietnamese patients. Methods: Two hundred and twelve colorectal cancer patients were included. Tumor tissues underwent hematoxylin and eosin staining, IHC staining (for four MMR proteins: MLH1, PMS2, MSH2, and MSH6), and PCR assay. Clinicopathological characteristics were collected and compared between dMMR tumors and their subtypes (dMutL and dMutS) with proficient MMR (pMMR). Firth’s logistic regression was conducted to construct the model predicting each subtype of dMMR based on clinicopathological characteristics. A PCR assay was performed on selected cases, and the concordance in MMR results between IHC and PCR was examined. Results: dMMR tumors accounted for 25.5% of total tumors. Compared to pMMR tumors, dMutL tumors showed differences in tumor location, vascular invasion, lymphovascular invasion, histopathologic grade, and pTNM stage, whereas dMutS tumors showed differences in tumor size and pTNM stage. MMR results between IHC and PCR showed high concordance (Kappa = 0.88, 95% CI: 0.78– 0.97), with IHC demonstrating 100% sensitivity, 87.5% specificity, and 88.9% precision relative to PCR. The dMutL predictive model exhibited good discrimination and calibration, but the dMutS model exhibited poor performance. Conclusion: dMMR status, especially dMutL, might be associated with clinicopathologic characteristics, which might support decision-making in clinical practice. These findings require validation in larger cohorts but may inform clinical screening practices in resource-limited settings.


  • Open Access

    The Role of Pan-Cytokeratin In Tumor Budding Upgrading In Malignant Colorectal Polyps At Stage pT1

    by Huy Le, Phat Ho, Hanh Ngo, Minh Dang, Thang Pham, Giang Tran, Duy Nguyen

    Tumor budding (TB) is an established prognostic factor in early colorectal cancer. However, its evaluation on hematoxylin–eosin (H&E) slides may underestimate the true budding activity. This study aimed to investigate the role of pan-cytokeratin (Pan-CK) immunohistochemistry in upgrading TB assessment in malignant colorectal polyps at the pT1 stage and to determine clinicopathological factors associated with TB upgrading. We retrospectively reviewed 104 malignant colorectal polyps at the pT1 stage diagnosed between January 2015 and June 2024 at the University Medical Center, Ho Chi Minh City. TB was assessed on H&E and Pan-CK stained slides according to the 2016 International Tumor Budding Consensus Conference (ITBCC) criteria. Cases were classified as Bd1 (0–4 buds), Bd2 (5–9 buds), or Bd3 (≥10 buds). Upgrading was defined as an increase in TB grade on Pan-CK compared with H&E, particularly evaluated among cases classified as Bd1 on H&E. Clinicopathological features associated with upgrading were analyzed using univariate and multivariate models. The number of tumor buds was significantly higher on Pan-CK compared with H&E (median [IQR] 1.0 [0.0–7.0] vs 0.5 [0.0–3.0]; p < 0.001). Among 90 cases classified as Bd1 on H&E, 25 (27.78%) were upgraded to Bd2/3 after Pan-CK staining. In univariate analysis, higher Haggitt/Kikuchi level and the presence of synchronous polyps were significantly associated with upgrading, whereas tumor grade 2 demonstrated a borderline association. Multivariate analysis identified synchronous polyps as the only independent predictor (OR = 3.00, 95% CI: 1.03–8.76; p = 0.045). Pan-CK substantially increases TB detection and grading in pT1 malignant colorectal polyps. Synchronous polyps were identified as the sole independent predictor of TB upgrading, representing a novel finding. Selective Pan-CK use in these cases may optimize resources and guide management.


  • Open Access

    CAAF-ResUNet: Adaptive Attention Fusion with Boundary-Aware Loss for Lung Nodule Segmentation

    by Thang Quoc Pham, Thai Hoang Le, Khai Dinh Lai, Dat Quoc Ngo, Tan Van Pham, Quang Hong Hua, Khang Quang Le, Huyen Duy Mai Le, Tuyen Ngoc Lam Nguyen

    Background and Objectives: The accurate segmentation of pulmonary nodules in computed tomography (CT) remains a critical yet challenging task due to variations in nodule size, shape, and boundary ambiguity. This study proposes CAAF-ResUNet (Context-Aware Adaptive Attention Fusion ResUNet), a novel deep learning model designed to address these challenges through adaptive feature fusion and edge-sensitive learning. Materials and Methods: Central to our approach is the Adaptive Attention Controller (AAC), which dynamically adjusts the contribution of channel and position attention based on contextual features in each input. To further enhance boundary localization, we incorporate three complementary boundary-aware loss functions: Sobel, Laplacian, and Hausdorff. Results: An extensive evaluation of two benchmark datasets demonstrates the superiority of the proposed model, achieving Dice scores of 90.88% on LUNA16 and 85.92% on LIDC-IDRI, both exceeding prior state-of-the-art methods. A clinical validation of a dataset comprising 804 CT slices from 35 patients at the University Medical Center of Ho Chi Minh City confirmed the model’s practical reliability, yielding a Dice score of 95.34% and a notably low Miss Rate of 4.60% under the Hausdorff loss configuration. Conclusions: These results establish CAAF-ResUNet as a robust and clinically viable solution for pulmonary nodule segmentation, offering enhanced boundary precision and minimized false negatives, two critical properties in early-stage lung cancer diagnosis and radiological decision support.


  • Open Access

    Characteristics of RET gene mutations in Vietnamese medullary thyroid carcinoma patients: a single-center analysis

    by Van Hung Pham, Quoc Thang Pham, Minh Nguyen, Hoa Nhat Ngo, Thao Thi Thu Luu, Nha Dao Thi Minh, Trâm Đặng, Anh Tu Thai, Hoang Anh Vu, Dat Quoc Ngo

    Background: The RET gene point mutation is the main molecular alteration involved in medullary thyroid carcinoma (MTC) tumorigenesis. Previous studies in Vietnam mainly consisted of case reports, with limited data on larger sample sizes. In this study, we investigated RET gene mutations in exons 10, 11, and 16 and analyzed clinicopathological features of a series of Vietnamese MTC patients. Methods: We collected 33 tissue samples from patients with MTC and analyzed RET mutations using the Sanger sequencing method. The relationship between hotspot RET mutations (exons 10, 11, 16) and clinicopathological features were investigated. Results: Among the 33 analyzed cases, 17 tumors (52%) harbored RET mutations in exon 10, 11, or 16. A total of 10 distinct genetic alterations were identified, including eight missense mutations and two short indels. Of these, seven were classified as pathogenic mutations based on previous publications, with p.M918T being the most frequent (4 cases), followed by p.C634R (3 cases) and p.C618R (3 cases). Mutations were significantly associated with specific histological patterns, such as the nested/insular pattern (p=.026), giant cells (p=.007), nuclear pleomorphism (p=.018), stippled chromatin (p=.044), and amyloid deposits (p=.024). No mutations were found in germline analyses, suggesting these were somatic alterations. Conclusions: Our results provided the first comprehensive analysis of RET mutations in Vietnamese MTC patients. The most frequent mutation was p.M918T, followed by p.C634R and p.C618R. Mutations in these three exons were linked to specific histopathological features. Information on mutational profiles of patients with MTC will further aid in the development of targeted therapeutics to ensure effective disease management.


  • Open Access

    Expression of PTEN protein in prostatic adenocarcinoma

    by Thanh Tu Duong, Quoc Thang Pham, Tan Buu Nguyen, Thanh Thien Ly, Ngoc Minh Tam Nguyen, Quoc Dat Ngo

    Background: PTEN protein is a new biomarker for identifying poor prognosis in prostatic adenocarcinoma. Objective: To evaluate the expression of PTEN protein in prostatic adenocarcinoma and assess the correlation between expression of PTEN protein with other clinicopathological characteristics in prostatic adenocarcinoma. Materials and methods: A descriptive analysis of 121 radical prostatectomy specimens diagnosed with prostatic adenocarcinoma at Binh Dan Hospital from January 2022 to December 2023. Interpret H&E and PTEN immunohistochemistry (IHC) slides. Analyse data and the correlation between clinicopathological and PTEN expression variables. Results: 72.7% of cases showed intact PTEN protein by IHC, while the rates of homogeneous and heterogeneous PTEN loss were 14.1% and 13.2%, respectively. Conclusion: Expression of PTEN protein was significantly associated with the 2019 International Society of Urological Pathology (ISUP) grade groups; however, there was no significant correlation between PTEN expression and other clinicopathological characteristics

  • Open Access

    Immunohistochemical Evaluation of Basal and Luminal Markers in Bladder Cancer: A Study from a Single Institution

    by Anh Toan Do, Quoc Thang Pham, Ngoc Minh Tam Nguyen, Phuc Nguyen Nguyen, Thi Thanh Tam Bui, Quoc Dat Ngo

    Background: Bladder cancer (BC) presents significant molecular diversity, which affects both prognosis and treatment results. Immunohistochemistry (IHC) facilitates the identification of molecular subtypes and their relationships with clinicopathological features. Methods: We performed an IHC analysis on tissue samples from 107 BC patients, evaluating the expression of markers GATA3, CD44, CK5/6, and CK20. We applied two methods to classify the tumor samples into basal and luminal subtypes. The relationships between these marker expressions, molecular subtypes, clinicopathological characteristics, and TILs were explored. Results: Most samples showed the expression of GATA3 and CD44, with notable correlations found between CD44 and CK5/6 as well as GATA3 and CK20. CD44 and CD20 expression were linked to a poorer prognosis. Additionally, the luminal and basal subtypes had distinct TIL patterns, which influenced overall survival. A poor prognosis was associated with the basal subtype with low TIL infiltration and the luminal subtype with high TIL infiltration. Conclusions: Our study clarifies the molecular characteristics of BC, underlining the prognostic importance of CD44 expression and the role of TILs in influencing subtype-specific outcomes. IHC proves valuable in subtype identification and supports personalized treatment strategies.


  • Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells

    by Quoc Thang Pham, Daiki Taniyama, Shintaro Akabane, Tsuyoshi Takashima, Ryota Maruyama, Yohei Sekino, Kazuhiro Sentani, Wataru Yasui, Naohide Oue

    Introduction: Tryptophan metabolism has been shown to be involved in tumor development. Two main tryptophan-degrading enzymes, tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1), may potently promote cancer cell survival and distant metastasis in diverse types of cancer, such as lung and breast cancer. IDO1 overexpression is an independent prognosticator in gastric cancer (GC). This work aimed to uncover the expression of TDO2 and its clinicopathologic significance in GC. Methods: TDO2 expression was evaluated in public data of The Cancer Genome Atlas cohort STAD and in two different GC cohorts. Correlation between TDO2 and immune cell infiltrates as well as PD-L1 tumor staining was investigated. The biofunction of TDO2 was examined with MTT, colony formation, and spheroid formation assays by RNA interference. Results: TDO2 expression was correlated with both progressive disease and clinical outcome, and its expression was an independent predictor of prognosis in GC. TDO2 expression was correlated with infiltration of immune cells and tumor expression of PD-L1. Inhibition of TDO2 expression suppressed cell proliferation, colony formation, and cell invasion of GC cells. Additionally, suppression of TDO2 expression inhibited spheroid body-formation and viability of GC organoids. Conclusion: Our data show that TDO2 might be a crucial marker for predicting prognosis and targeted therapy in GC.


  • Open Access

    Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy

    by Daiki Taniyama, Naoya Sakamoto, Tsuyoshi Takashima, Masahiko Takeda, Quoc Thang Pham, Shoichi Ukai, Ryota Maruyama, Kenji Harada, Takashi Babasaki, Yohei Sekino, et al.

    The utility of Schlafen 11 (SLFN11) expression as a predictive biomarker for platinum‐based chemotherapy has been established for cancers from different histologies. However, the therapeutic relevance of SLFN11 in bladder cancer (BC) is unknown. Here, we examined the clinicopathologic significance of SLFN11 expression across 120 BC cases by immunohistochemistry. We divided the cases into two cohorts, one including 50 patients who received adjuvant or neoadjuvant platinum‐based chemotherapy, and the other including 70 BC patients treated by surgical resection without chemotherapy. In the cohort of 50 BC cases treated with platinum‐based chemotherapy, the SLFN11‐positive group (n = 25) showed significantly better overall survival than the SLFN11‐negative group (n = 25, P = .012). Schlafen 11 expression correlated significantly with the expression of luminal subtype marker GATA3. Multivariate analyses identified SLFN11 expression as an independent prognostic predictor (odds ratio, 0.32; 95% confidence interval, 0.11‐0.91; P = .033). Conversely, in the cohort of 70 BC cases not receiving platinum‐based chemotherapy, the SLFN11‐positive group (n = 29) showed significantly worse overall survival than the SLFN11‐negative group (n = 41, P = .034). In vitro analyses using multiple BC cell lines confirmed that SLFN11 KO rendered cells resistant to cisplatin. The epigenetic modifying drugs 5‐azacytidine and entinostat restored SLFN11 expression and resensitized cells to cisplatin and carboplatin in SLFN11‐negative BC cell lines. We conclude that SLFN11 is a predictive biomarker for BC patients who undergo platinum‐based chemotherapy and that the combination of epigenetic modifiers could rescue refractory BC patients to platinum derivatives by reactivating SLFN11 expression.


  • Open Access

    KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer

    by Yohei Sekino, Quoc Thang Pham, Kohei Kobatake, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Tetsutaro Hayashi, Hikaru Nakahara, Kazuhiro Sentani, Naohide Oue, et al.

    Kinesin family member C1 (KIFC1), a minus end-directed motor protein, is reported to play an essential role in cancer. This study aimed to analyze KIFC1 expression and examine KIFC1 involvement in cisplatin resistance in bladder cancer (BC). Immunohistochemistry showed that 37 of 78 (47.4%) BC cases were positive for KIFC1. KIFC1-positive cases were associated with high T stage and lymph node metastasis. Kaplan-Meier analysis showed that KIFC1-positive cases were associated with poor prognosis, consistent with the results from public databases. Molecular classification in several public databases indicated that KIFC1 expression was increased in basal type BC. Immunohistochemistry showed that KIFC1-positive cases were associated with basal markers 34βE12, CK5 and CD44. KIFC1 expression was increased in altered TP53 compared to that in wild-type TP53. Immunohistochemistry showed that KIFC1-positive cases were associated with p53-positive cases. P53 knockout by CRISPR-Cas9 induced KIFC1 expression in BC cell lines. Knockdown of KIFC1 by siRNA increased the sensitivity to cisplatin in BC cells. Kaplan-Meier analysis indicated that prognosis was poor among KIFC1-positive BC patients treated with cisplatin-based chemotherapy. Immunohistochemistry showed that KIFC1-positive cases were associated with PD-L1-positive cases. High KIFC1 expression was associated with a favorable prognosis in patients treated with atezolizumab from the IMvigor 210 study. These results suggest that KIFC1 might be a promising biomarker and therapeutic target in BC.